Form 4: Lantheus Holdings Chief Medical Officer Reports Stock Disposal
SEC Form 4 Filing
Jean-Claude Provost, Chief Medical Officer of Lantheus Holdings, Inc., reported disposing of 546 shares of common stock on March 5, 2024, for tax purposes.
Summary
- On March 5, 2024, Jean-Claude Provost, the Chief Medical Officer of Lantheus Holdings, Inc., disposed of 546 shares of common stock.
- The transaction was executed at a price of $65.36 per share.
- The shares were disposed of indirectly through Theranostics Consulting SAS.
- Following the transaction, Provost indirectly owns 38,841 shares of Lantheus Holdings, Inc.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing regarding stock transactions. It doesn't convey any explicit positive or negative sentiment about the company's performance or prospects.
Industry Context
This filing is a routine disclosure of stock transactions by a company insider and doesn't necessarily indicate a significant trend or event within the pharmaceutical industry.
Stakeholder Impact
- The transaction is unlikely to have a significant impact on stakeholders.
Key Dates
| Date | Description |
|---|---|
| 03/05/2024 | Date of stock disposal transaction |
| 03/07/2024 | Date of signature for the SEC filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.